US FDA issues J&J with complete response letter for carisbamate
This article was originally published in Scrip
Executive Summary
The US FDA has hit Johnson & Johnson with a complete response letter for its anti-epileptic Comfyde (carisbamate). The company has not disclosed the contents, but did say it was evaluating the letter and would "respond to the agency's questions as quickly as possible".